Biotechnology News and Research

RSS

Heavily congested highway correlates with higher rates of asthma

Researchers at SUNY Downstate Medical Center and Lutheran Medical Center in Brooklyn, New York, found that living near a heavily congested highway correlates with a higher presence of asthma.

27 Jun 2012

RXi Pharmaceuticals initiates RXI-109 Phase 1 trial to reduce surgical scars

RXi Pharmaceuticals Corporation today announced that it successfully initiated its first ever clinical study with an RNAi compound, RXI-109, using their proprietary self-delivering RNAi technology.

27 Jun 2012

Report on the global market for breast cancer diagnostics and drug technologies

Breast Cancer Diagnostic and Drug market are recovering after significant slowdown during the global recession. Having accurate market data and analysis will be essential to companies seeking to compete on the global stage as the market reemerges into success.

26 Jun 2012

Biological filter to remove estrogens from waste water and drinking water

A biological filter to remove estrogens from waste water and drinking water. The 15 Bielefeld students submitting this project to the 'international Genetically Engineered Machine competition' (iGEM) at the Massachusetts Institute of Technology (MIT) in Boston, USA are setting their sights high.

26 Jun 2012

Nanoparticles that can slip through mucus barriers shown to protect against herpes infections

Johns Hopkins researchers say they have demonstrated, for the first time in animals, that nanoparticles can slip through mucus to deliver drugs directly to tissue surfaces in need of protection. The researchers used these mucus-penetrating particles (MPPs) to protect against vaginal herpes infections in mice and the goal is to create similar MPPs to deliver drugs that protect humans against sexually transmitted diseases or even treat cancer.

26 Jun 2012

BioImageXD software can help analyze cell and tissue functions

Researchers in Finland and Germany have developed an open-source software that will make it significantly easier to process bioimaging data. The software, named BioImageXD, will help in analysing cell and tissue functions.

26 Jun 2012

CCI, NextBio partner to adopt genomics in the clinic

NextBio and Cancer Care Institute (CCI) announced today a strategic partnership aimed at furthering the adoption of genomics in the clinic. The collaboration will facilitate use of the NextBio platform to interpret genomic molecular data for oncology patients and streamline the complete workflow for use of molecular data in a clinical setting.

26 Jun 2012

Amgen launches Chemotherapy: Myths or Facts campaign for cancer patients

Amgen today launched Chemotherapy: Myths or Facts, an awareness campaign for cancer patients and their caregivers featuring Emmy-nominated actress and breast cancer survivor Maura Tierney.

26 Jun 2012

Merck Serono, Compugen announce establishment of Neviah Genomics

Merck Serono, a division of Merck, Darmstadt, Germany, and Compugen Ltd. today announced the establishment of Neviah Genomics, a novel start-up company focused on the discovery and development of novel biomarkers for the prediction of drug-induced toxicity.

26 Jun 2012

Affymetrix acquires eBioscience

Affymetrix Inc., today announced that the Company has completed its acquisition of eBioscience Holding Company, Inc., a privately-held company with an industry-leading position in flow cytometry and immunoassay reagents for immunology and oncology research and diagnostics.

26 Jun 2012

FDA approves Baxter's GAMMAGARD LIQUID for multifocal motor neuropathy

Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] as a treatment for multifocal motor neuropathy (MMN). This is the first immunoglobulin treatment approved for MMN patients in the United States, and it was approved for use with MMN patients in Europe in 2011.

From Baxter International Inc. 25 Jun 2012

Researchers create endothelial cells with blood-brain barrier qualities

The blood-brain barrier -- the filter that governs what can and cannot come into contact with the mammalian brain -- is a marvel of nature. It effectively separates circulating blood from the fluid that bathes the brain, and it keeps out bacteria, viruses and other agents that could damage it.

25 Jun 2012

U.S. District Court rules in favor of Teva in COPAXONE patent infringement case

Teva Pharmaceutical Industries Ltd. announced today the U.S. District Court for the Southern District of New York has found in favor of Teva in the Company's patent infringement lawsuit against Momenta Pharmaceuticals, Inc./Sandoz Inc. and Mylan Laboratories Inc./Natco Pharmaceuticals regarding Teva's relapsing-remitting multiple sclerosis (RRMS) product, COPAXONE.

23 Jun 2012

Rensselaer Center for Stem Cell Research launches today

Ground-breaking research to advance the application of stem cells to address critical injuries and diseases will be taking place at Rensselaer Polytechnic Institute, in a new center funded by New York state and opened today.

From Thermo Fisher Scientific Inc. 23 Jun 2012

Genentech's Perjeta helps people with HER2-positive metastatic breast cancer live longer

Genentech, a member of the Roche Group, announced today that people with HER2-positive metastatic breast cancer (mBC) lived significantly longer (overall survival) when treated with the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy, compared to Herceptin and docetaxel chemotherapy alone in the Phase III CLEOPATRA study.

23 Jun 2012

FDA issues CRL to Repligen's RG1068 NDA for treatment of pancreatitis

Repligen Corporation today announced that it has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) regarding the Company's New Drug Application (NDA) for RG1068.

23 Jun 2012

Research funding in sub-Saharan Africa needs to 'reflect true disease burden'

With the disease burden of AIDS, tuberculosis, and malaria expected to make up less than 15 percent of the total disease burden in sub-Saharan Africa (SSA) by 2030, and non-communicable diseases to account for nearly 40 percent of the total in the region, "[a] revision of the approach to research and health care in SSA is therefore urgently needed, but international donors and health communities have generally been slow to respond to the changing environment."

22 Jun 2012

New melatonin analogues more efficient in inhibiting NOS activity in Parkinson's disease

University of Granada researchers have tested melatonin analogues in rats as it inhibits the enzyme nitric oxide synthase (NOS), which is involved in the development of conditions as inflammatory bowel disease, septic shock or rheumatoid arthritis, as well as in neurodegenerative conditions as Huntington's disease, Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.

22 Jun 2012

Teva launches Olanzapine and Fluoxetine Capsules for treatment of depression

Teva Pharmaceutical Industries Ltd. announced today the launch of Olanzapine and Fluoxetine Capsules USP 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg, and 12 mg/50 mg, the Company's generic equivalent of Symbyax.

22 Jun 2012

UMMS researcher receives Janssen Award for microRNA discovery

Longtime collaborators Victor R. Ambros, PhD, of the University of Massachusetts Medical School (UMMS) and Gary B. Ruvkun, PhD, of Massachusetts General Hospital and Harvard Medical School, were awarded the 2012 Dr. Paul Janssen Award for Biomedical Research today by Johnson & Johnson for their co-discovery of microRNA, tiny molecules that are now understood to play a powerful role in gene expression and regulation.

20 Jun 2012